CD276 and acute myeloid leukemia: Finally, since anthracycline-based first induction therapy is the classical and most frequently used treatment regimen for AML patients in our cohort (59.7% of all treatments), but also in general [18], we propose considering B7-H3 as a negative prognostic marker for AML, independent of the treatment regimen.